We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+23.37%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
–
Cap. Flow
+$239M
Cap. Flow
% of AUM
85.54%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
170
New
170
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$36.3M |
| 2 |
Keros Therapeutics
KROS
|
+$21.6M |
| 3 |
Roivant Sciences
ROIV
|
+$12.2M |
| 4 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
+$6.94M |
| 5 |
Arbutus Biopharma
ABUS
|
+$6.79M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.64% |
| 2 | Technology | 1.12% |
| 3 | Financials | 1.12% |
| 4 | Materials | 0.99% |
| 5 | Consumer Staples | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
| $43.8M | 15.64% |
+228,600
| New | +$38.9M |
|
|
2
Royalty Pharma
RPRX
$26.2B
| $37.1M | 13.27% |
+1,321,834
| New | +$36.3M |
|
|
3
Keros Therapeutics
KROS
$197M
| $27.4M | 9.78% |
+688,316
| New | +$21.6M |
|
|
4
Roivant Sciences
ROIV
$23.6B
| $14.1M | 5.04% |
+1,256,591
| New | +$12.2M |
|
|
5
Arbutus Biopharma
ABUS
$845M
| $8.67M | 3.1% |
+3,468,824
| New | +$6.79M |
|
6
Cytokinetics
CYTK
$10.6B
| $7.69M | 2.75% |
+92,082
| New | +$3.33M |
|
7
BridgeBio Pharma
BBIO
$16.4B
| $7.47M | 2.67% |
+185,137
| New | +$5.56M |
|
|
MACK
8
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $7.37M | 2.63% |
+549,418
| New | +$6.94M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.34M | 2.27% |
+108,000
| New | +$6.07M |
|
|
10
CALL
Cytokinetics
CYTK
$10.6B
| $6.11M | 2.18% |
+73,200
| New | +$2.65M |
|
11
Merck
MRK
$322B
| $5.89M | 2.1% |
+54,000
| New | +$5.61M |
|
12
Ascendis Pharma A/S
ASND
$16.5B
| $5.78M | 2.07% |
+45,884
| New | +$4.57M |
|
13
Immunovant
IMVT
$7.93B
| $5.65M | 2.02% |
+134,125
| New | +$4.94M |
|
14
Viking Therapeutics
VKTX
$3.89B
| $4.73M | 1.69% |
+254,151
| New | +$3.32M |
|
|
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.69M | 1.68% |
+110,700
| New | +$3.18M |
|
16
Protagonist Therapeutics
PTGX
$8.54B
| $4.61M | 1.65% |
+200,859
| New | +$3.51M |
|
17
Fulcrum Therapeutics
FULC
$242M
| $4.3M | 1.54% |
+637,405
| New | +$2.83M |
|
18
Cellectar Biosciences
CLRB
$20M
| $3.82M | 1.36% |
+45,936
| New | +$3.42M |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $3.17M | 1.13% |
+10,000
| New | +$1.94M |
|
20
OmniAb
OABI
$284M
| $2.95M | 1.05% |
+478,171
| New | +$2.35M |
|
|
AYX
21
DELISTED
Alteryx Inc
AYX
| $2.93M | 1.05% |
+62,038
| New | +$2.41M |
|
22
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
| $2.92M | 1.05% |
+32,000
| New | +$2.93M |
|
23
WisdomTree Floating Rate Treasury Fund
USFR
$18.1B
| $2.81M | 1.01% |
+56,000
| New | +$2.82M |
|
24
Corteva
CTVA
$60.5B
| $2.78M | 0.99% |
+58,000
| New | +$2.77M |
|
25
iShares 0-1 Year Treasury Bond ETF
SHV
$20.8B
| $2.7M | 0.96% |
+24,500
| New | +$2.7M |
|
Similar funds
RSCM
AAM
SGI
BCM
ISS
FDP
PP
GAM
ADAR1 Capital Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for ADAR1 Capital Management, which disclosed 170 positions worth $280M. Its ten largest holdings account for 59% of the portfolio.
Its largest position is Royalty Pharma: 1,321,834 shares worth $37.1M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, followed by Technology and Financials.
- ADAR1 Capital Management's largest Q4 2023 buy was Royalty Pharma: 1,321,834 shares worth $37.1M.
- ADAR1 Capital Management's ten largest holdings make up 59% of its $280M portfolio in Q4 2023.
- ADAR1 Capital Management disclosed 170 positions in Q4 2023, its first 13F filing on record.
Based on ADAR1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.